CALA vs. NAVB, SCPS, EVLO, CMRA, GNCAQ, GNCA, ARDS, STAB, SMFL, and AMPE
Should you be buying Calithera Biosciences stock or one of its competitors? The main competitors of Calithera Biosciences include Navidea Biopharmaceuticals (NAVB), Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), Smart for Life (SMFL), and Ampio Pharmaceuticals (AMPE). These companies are all part of the "pharmaceutical products" industry.
Calithera Biosciences vs.
Navidea Biopharmaceuticals (NYSE:NAVB) and Calithera Biosciences (NASDAQ:CALA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.
0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Comparatively, 6.6% of Calithera Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, Calithera Biosciences had 1 more articles in the media than Navidea Biopharmaceuticals. MarketBeat recorded 1 mentions for Calithera Biosciences and 0 mentions for Navidea Biopharmaceuticals. Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Calithera Biosciences'average media sentiment score.
Navidea Biopharmaceuticals has higher revenue and earnings than Calithera Biosciences.
Navidea Biopharmaceuticals has a beta of 2.04, indicating that its stock price is 104% more volatile than the S&P 500. Comparatively, Calithera Biosciences has a beta of -1.13, indicating that its stock price is 213% less volatile than the S&P 500.
Calithera Biosciences received 341 more outperform votes than Navidea Biopharmaceuticals when rated by MarketBeat users. Likewise, 55.36% of users gave Calithera Biosciences an outperform vote while only 0.00% of users gave Navidea Biopharmaceuticals an outperform vote.
Summary
Navidea Biopharmaceuticals beats Calithera Biosciences on 5 of the 8 factors compared between the two stocks.
Get Calithera Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CALA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Calithera Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:CALA) was last updated on 5/2/2025 by MarketBeat.com Staff
